Low incidence of severe acute and chronic graft-versus-host disease in a long-term retrospective study with ATG Grafalon routine use

Ann Hematol. 2023 Dec;102(12):3587-3591. doi: 10.1007/s00277-023-05479-w. Epub 2023 Oct 3.

Abstract

Since 2006, combined graft-versus-host disease (GVHD) prophylaxis with ATG Grafalon has been our department's base of peri-transplant supportive care. This recent retrospective study included 398 patients who underwent their first allogeneic hematopoietic stem cell transplantation after receiving a defined dose of ATG Grafalon. Our observations recorded reduced incidence of severe acute and chronic GVHD without negative impact on overall survival in a nonselected group with standard and uniform GVHD prophylaxis.

Keywords: ATG Grafalon; Acute and chronic GVHD; AlloHSCT.

MeSH terms

  • Antilymphocyte Serum / therapeutic use
  • Bronchiolitis Obliterans Syndrome*
  • Graft vs Host Disease* / epidemiology
  • Graft vs Host Disease* / etiology
  • Graft vs Host Disease* / prevention & control
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Humans
  • Incidence
  • Retrospective Studies
  • Transplantation Conditioning / adverse effects
  • Transplantation, Homologous / adverse effects

Substances

  • Antilymphocyte Serum